Overall rank by patents
#8,520
of 50,000 tracked assignees
USPTO PatentsView assignee record - 38 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
According to USPTO PatentsView, Ziemer ranks #8,520 of 50,000 tracked US assignees by granted-patent volume, with 38 patents across 8 technology areas.
USPTO PatentsView assignee plate
Corpus R8520 · Foreign Corporation #8,520 · 38 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: XEVO Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
American Internation… · near
38 score
Cyberlink · near
38 score
Honey BEE Manufactur… · near
38 score
Legrand AV · near
38 score
Ziemer Ophthalmic Sy… · this assignee
38 score
3D Lighting Innovati… · lowest
7 score
What this shows Ziemer Ophthalmic Systems Ag stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-NARROW, INNOV-THIN, CLAIMS-RICH, TYPE-FRNCORP, VEL-SURGE, BOOK-FULL. Volume places it #8,520 of 50,000; Innovation Score 38.2/100 sits in the top 41% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is XEVO Inc. (±0 grants).
Ziemer Ophthalmic Systems Ag has been granted 38 US utility patents between 2015 and 2025, placing Ziemer Ophthalmic Systems Ag at #8,520 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.9 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, Ziemer Ophthalmic Systems Ag is one of the more focused assignees in the PatentsView dataset. By volume, Ziemer sits between XEVO Inc. (38 patents, rank #8,516) and Allnex Austria Gmbh (37 patents, rank #8,524) - the closest US assignees by grant volume. The composite Innovation Score of 38.2/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 25 grants, compared with 8 in the 2015–2019 window, a +213% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Ziemer Ophthalmic Systems Ag's 16.9 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 8 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
XEVO INC.
38 patents
YEXT, INC.
38 patents
Yieldmo, Inc.
38 patents
ZHEJIANG DUNAN ARTIFICIAL ENVIRONMENT CO., LTD.
38 patents
Ziemer Ophthalmic Systems AG
38 patents
7RDD Limited
37 patents
ABS Global, Inc.
37 patents
ABT, Inc.
37 patents
ALLNEX AUSTRIA GMBH
37 patents
What this shows Ziemer holds 38 patents at rank #8,520, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #8,520 in granted patent volume.
Other assignees with the most granted patents in Ziemer's primary technology class.
Two PlainPatent-derived peer sets for Ziemer, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (38 here).
Ziemer's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
38 Top 41% higher than 59% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 2.6% |
| 2016 | 1 | 2.6% |
| 2017 | 2 | 5.3% |
| 2019 | 4 | 10.5% |
| 2020 | 7 | 18.4% |
| 2021 | 5 | 13.2% |
| 2022 | 4 | 10.5% |
| 2023 | 6 | 15.8% |
| 2024 | 3 | 7.9% |
| 2025partial year | 5 | 13.2% |
Top 8 of 8 technology areas
Overall rank by patents
#8,520
of 50,000 tracked assignees
38.2 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.